
Curriculum Vitae – Dr. Marcello A. Tonelli

Contact Information

Mailing Address: University of Alberta, Department of Medicine,
Division of Nephrology and Immunology
Clinical Sciences Building 7-129
Edmonton, AB T6G 2G3

Phone/Fax/email: Ph: (780) 407-8520; Fax: (780) 407-7878
Email: mtonelli@ualberta.ca

Place/Date of Birth: Ontario, Canada – June 7, 1971
Canadian citizen

Education

1989 – 1991 University of Western Ontario, Faculty of Science
London, Canada

1991-1995 University of Western Ontario, Faculty of Medicine
London, Canada
M.D. awarded June 1995

Postdoctoral Training

Residency:
1995-1998 University of Western Ontario, Faculty of Medicine
London, Canada
Internal Medicine, Core Training Program

1998-2000 Dalhousie University, Faculty of Medicine
Halifax, Canada
Nephrology Subspecialty Training Program

Masters' of Science:
2000-2002 Harvard School of Public Health
Boston, USA
Supervisor: Dr. Gary Curhan
SM, Clinical Epidemiology

Research Fellowship:
2000-2002 Kidney Foundation of Canada/Baxter Corporation Biomedical
Research Fellowship
Dalhousie University, Faculty of Medicine
Halifax, Canada
Supervisor: Dr. Kailash Jindal

Licensure

2007	Medical licensure, Republic of Kenya
2002	Internal Medicine/Nephrology, Province of Alberta
2000	Specialist Certification in Nephrology, Royal College of Physicians and Surgeons of Canada
1999	Specialist Certification in Internal Medicine, Royal College of Physicians and Surgeons of Canada

Academic/Professional Appointments

2007 -	Associate Professor, University of Alberta Department of Medicine, Division of Nephrology and Immunology Edmonton, Canada
2007 -	Associate Professor, University of Alberta Faculty of Medicine, Public Health Sciences Edmonton, Canada
2007 -	Associate Professor, University of Alberta Stand-Alone Divisions, Critical Care Medicine Edmonton, Canada
2004-	Faculty Member, EPICORE Center University of Alberta Department of Medicine, Division of Cardiology Edmonton, Canada
2004 -2007	Adjunct Assistant Professor, University of Alberta Faculty of Medicine, Public Health Sciences Edmonton, Canada
2003-2007	Adjunct Assistant Professor, University of Alberta Stand-Alone Divisions, Critical Care Medicine Edmonton, Canada
2003-2004	Research Fellow, Institute of Health Economics Edmonton, Canada
2002-2007	Assistant Professor, University of Alberta Department of Medicine, Division of Nephrology and Immunology Edmonton, Canada
2002-	Staff Nephrologist, University of Alberta Hospital, Capital Health Edmonton, Canada

Honours and Awards

International Awards:

- **Research Travel Scholarship (Research award)**
International Society of Nephrology (ISN), 2003.

Postgraduate Awards:

- **Trainee Research Award (National award)**
Canadian Society of Nephrology (CSN), Canada; 2002.
Amount awarded: \$500.
- **Trainee Research Award (National award)**
Canadian Society of Nephrology (CSN), Canada; 2001.
Amount awarded: \$500.
- **Clinical Traineeship Award (National award)**
Royal College of Physicians and Surgeons of Canada, Canada; 2001.
Amount awarded: \$3,000.
- **University Internal Medicine Research Fellowship (University award)**
Dalhousie University, Canada; 2000.
Amount awarded: \$18,000.
- **Biomedical Research Fellowship (National award)**
Kidney Foundation of Canada, 2000.
Amount awarded: \$90,000.
- **Best Presentation, Subspecialty Resident (University award)**
Internal Medicine Residents' Research Day, 1999.
Dalhousie University, Canada.
Amount awarded: \$500.
- **Medical Research Award (University award)**
Dalhousie University Alumni, 1999.
Amount awarded: \$2,500.
- **Excellence in Clinical Teaching (Provincial award)**
Professional Association of Interns and Residents of Ontario (Canada), 1998.
- **Trainee Research Award (National award)**
Canadian Society of Nephrology (CSN), Canada; 1997.
Amount awarded: \$500.
- **Best Presentation, Internal Medicine (University award)**
Internal Medicine Research Day, 1996.
University of Western Ontario, Canada; 1996.
Amount awarded: \$500.

Medical School:

- **Rachel Slobasky-Kaplan - Highest Standing, Year II (Academic award)**
University of Western Ontario, Faculty of Medicine, Canada; 1993.
Amount awarded: \$500.
- **Dean's Honor List (Academic award)**
University of Western Ontario, Faculty of Medicine, Canada; 1992.

SUPERVISION OF TRAINEES

External examiner:

PhD Thesis Defense Committee. Department of Public Health Sciences, University of Alberta. Candidate: Dean Eurich; Supervisor: Jeff Johnson.

PhD Thesis Defense Committee. Faculty of Medicine, University of Calgary. Candidate: Linda Seidel; Supervisor: William Ghali.

MSc Thesis Defense Committee. Faculty of Nursing, University of Alberta. Candidate: Teddie Tanguay; Supervisor: Louise Jensen.

MSc Thesis Defense Committee. Faculty of Medicine, University of Calgary. Candidate: Brendan Murphy; Supervisor: Braden Manns.

Supervisor:

Matthew James, PhD Candidate. Department of Community Health Sciences, University of Calgary. (co-supervisor).

Manuscript: James M, Conley J, Tonelli M, Manns B, MacRae J, Hemmelgarn B; Alberta Kidney Disease Network. *Meta-analysis: antibiotics for prophylaxis against hemodialysis catheter-related infections.* Ann Intern Med. 2008 Apr 15;148(8):596-605.

Darcie Kiddoo, MSc Candidate. School of Public Health, University of Alberta.

Jennifer Krebs, MSc 2006-2008. School of Public Health, University of Alberta.

G. Al-Ghamdi, Post-graduate medical trainee 2007-.

Poster presentation: Al-Ghamdi G, Pannu N, Hemmelgarn B, Klarenbach S, Wiebe N, **Tonelli M.** “*Higher dialysate potassium is associated with increased risk of death in hemodialysis patients*”. Canadian Society of Nephrology Meeting; Halifax, Canada; May 2007.

M. Al-Ghonaim, Post-graduate medical trainee 2006-7.

Manuscript: Al-Ghonaim M, Manns B, Hirsch D, Gao Z, **Tonelli M;** for the Alberta Kidney Disease Network. *Relation between access blood flow and mortality in chronic hemodialysis patients.* Clin J Am Soc Nephrol. Epub 2008 Jan 30.

Oral presentation: Al-Ghonaim M, Manns B, Hirsch D, Gao Z, **Tonelli M.** “*Relation between access blood flow and mortality in chronic hemodialysis patients.*” Canadian Society of Nephrology Meeting, 2006.

S. Shurraw, Post-graduate medical trainee 2005-7.

Manuscript: Shurraw S, **Tonelli M.** *Statins for treatment of dyslipidemia in chronic kidney disease.* Perit Dial Int. 2006 Sep-Oct; 26(5):523-39.

Oral presentation: Shurraw S, Majumdar M, Hemmelgarn B, **Tonelli M.** “*Association between glucose, HbA1c and death in chronic hemodialysis patients.*” Canadian Society of Nephrology Meeting, 2006.

Award: Top trainee presentation. Canadian Society of Nephrology, 2006.

Award: Best research presentation by a subspecialty resident. Department of Medicine, University of Alberta 2006.

S. Sandhu, Post-graduate medical trainee 2005-6.

Manuscript: Sandhu S, Wiebe N, Fried L, **Tonelli M.** *Statins for improving renal outcomes: a meta-analysis.* J Am Soc Nephrol. 2006 Jul; 17(7):2006-16.

Oral presentation: Sandhu S, Wiebe N, Fried L, **Tonelli M.** “*Statins for improving renal outcomes: a meta-analysis.*” American Society of Nephrology Meeting, 2005.

Award: Best trainee research project, University of Alberta Anesthesia Residency Training Program, 2005.

Award: Postgraduate Medical Education Research Prize, University of Alberta Hospital, 2005.

J. Bradley, Post-graduate medical trainee 2003-4.

Manuscript: Chou S, **Tonelli M**, Bradley J, Gourishankar S, Hemmelgarn B; for the Alberta Kidney Disease Network. *Quality of Care among Aboriginal Hemodialysis Patients.* Clin J Am Soc Nephrol. 2006 Jan; 1(1):58-63.

Manuscript: **Tonelli M**, Chou S, Gourishankar S, Jhangri G, Bradley J, Hemmelgarn B. *Wait-listing for kidney transplantation among Aboriginal hemodialysis patients.* Am J Kidney Dis. 2005 Dec; 46(6):1117-23.

Poster presentation: Bradley J, Hemmelgarn B, Gourishankar S, **Tonelli M.** “*Quality of Hemodialysis Care in Aboriginal Patients.*” Canadian Society of Nephrology Meeting; Toronto, Canada; May 2004.

M. Fok, CIHR Summer Studentship 2003-4.

Manuscript: **Tonelli M**, Wiebe N, Culleton B, House A, Rabbat C, Fok M, McAlister F, Garg A. *Chronic kidney disease and mortality risk: a systematic review.* JASN. 2006 Jul; 17(7):2034-47.

I. Rapchuk, Post-graduate medical trainee 2002-3.

Manuscript: Rapchuk I, Rabuka S, **Tonelli M.** *Perioperative Use of Beta-blockers among Suitable Candidates Remains Low: Experience of a Single Canadian Tertiary Institution.* Can J Anaesth. 2004 Oct; 51(8):761-7.

Award: Best trainee presentation, Dalhousie Anesthesia Residency Training Program, 2003.

Formal Mentorship of Junior Faculty:

Justin Ezekowitz, Candidate for AHFMR Population Health Investigator Award.

Department of Medicine, University of Alberta. (internal grant review panel 2007; 2008).

Todd Alexander, Candidate for AHFMR Population Health Investigator Award.

Department of Pediatrics, University of Alberta. (primary mentor 2008-).

Catherine Morgan, Clinician-Investigator. Department of Pediatrics, University of Alberta. (primary mentor 2007-).

RESEARCH

Invited Presentations

Conferences and Visiting Speaker:

- **Asociación Nacional de Nefrologos de Mexico**
“Protocol-driven care for prevention of chronic kidney disease”
Queretaro, Mexico, May 2008.
- **Meeting on Hypertension, Diabetes and Renal Diseases, Annual Meeting**
“Statins and cardiovascular and renal protection: is it all in the LDL levels?”
Genoa, Italy, February 2008.
- **Dalhousie University.**
 - Medical Grand Rounds: “Statins in chronic kidney disease”
 - Nephrology Grand Rounds: “Geography and health in chronic kidney disease”
Halifax, Canada, January 2008.
- **University of Western Ontario.**
 - Nephrology journal club: “Statins for prevention of kidney function loss”
 - Nephrology Grand Rounds: “Geography and health in chronic kidney disease”
London, Canada, January 2008.
- **ISN Update Course in Nephrology**
 - Workshop: “Management of progression of CKD: Are ACE I and ARBs always justified?”
 - Invited speaker (debate): “Phosphate Control – Traditional vs Non-traditional
Dubai, United Arab Emirates, December 2007.
- **Visiting Professor, MP Shah Hospital**
“Options for renal replacement therapy in the ICU”
Nairobi, Kenya, December 2007.
- **Visiting Professor, Aga Khan University Hospital**
“ACE Inhibitors/ARBs in Chronic Kidney Disease”
Nairobi, Kenya, December 2007.
- **Visiting Professor, Nairobi Hospital (Roche)**
“Contrast Nephropathy”
Nairobi, Kenya, December 2007.
- **Invited Speaker, Kenyan Society of Nephrology**
“Setting up preventive nephrology programs in developing countries”
Nairobi, Kenya, December 2007.
- **Visiting Professor, Kenyatta National Hospital**
“ACE Inhibitors/ARBs in Chronic Kidney Disease”
Nairobi, Kenya, December 2007.
- **39th Course on Advances in Nephrology and Dialysis**
“Controllo della dislipidemia – Statine e fibrati”
Milan, Italy, December 2007.
- **American Society of Nephrology, Annual Meeting**
“Treatment of Atherosclerotic CVD in Advanced CKD”
San Francisco, California, November 2007.
- **Drugs Affecting Lipid Metabolism, International Symposium**
“Does Hypolipemic Therapy Benefit the Kidney as Well as the Heart?”
New York City, New York, October 2007.
- **European Renal Association/European Dialysis and Transplantation Association, Annual Meeting**
“Surrogate outcomes in the nephrology literature”
Barcelona, Spain, June 2007.

- **University of Toronto (Sunnybrook-University Health Network Site)**, Nephrology Grand Rounds
“Statins in chronic kidney disease”
Toronto, Canada, June 2007.
- **American Society of Nephrology**, Annual Meeting
“Hyperlipidemia and Progression of Kidney Disease: What Have We Learned from the Randomized Trials”
San Diego, California, November 2006.
- **Kidney Foundation of Canada – Wine Tasting Gala Fundraising Event**
“Chronic Kidney Disease”
Edmonton, Canada, November 2006.
- **Kidney Foundation of Canada – Focus on Research**
“Geography and Health for Canadians with Kidney Disease”
Edmonton, Canada, October 2006.
- **Canadian Society of Nephrology**, Annual Meeting
“Co morbidities Do Not Influence Primary Fistula Success in a Prospective Cohort in Southern Alberta”
Quebec City, Canada, May 2006.
- **Nephrology Grand Rounds**, Ottawa Hospital, Division of Nephrology
“Lipid lowering therapy in dialysis patients after the 4D trial”.
Ottawa, Canada, May 2006.
- **Oxford University Clinical Trials Unit/SHARP Collaborators Meeting**
“Dyslipidemia and Progression of Chronic Kidney Disease”
Oxford, England, March 2006.
- **Vanguard of Hemodialysis Conference**,
“Costs of Vascular Access”
“Inflammation in Chronic Kidney Disease”
Guadalajara, Mexico, March 2006.
- **Cardiology Grand Rounds**, Brigham and Women’s Hospital, Division of Cardiology
“Dyslipidemia and the Progression of Chronic Kidney Disease”
Boston, USA, January 2006.
- **Nephrology Journal Club**, Brigham and Women’s Hospital
“Randomized Trials in Nephrology”
Boston, USA, January 2006.
- **American Society of Nephrology**, Basic and Clinical Science Symposium.
“Inflammation, Dyslipidemia and the Kidney.”
Philadelphia, USA, November 2005.
- **Visiting Professor**, Tufts University, New England Medical Center
“Dyslipidemia and Progression of Chronic Kidney Disease.”
Boston, USA, September 2005.
- **Canadian Society of Nephrology National Meeting Satellite Symposium**
“Vascular Access – Now and Beyond: An Update by Canadian Nephrologists for Canadian Nephrologists.”
“The Future of Vascular Access Management and Adequacy – What are the Standards?”
Calgary, Canada, May 2005.
- **Citywide Nephrology Rounds**.
“Dyslipidemia and Progression of Chronic Kidney Disease.”
Queen’s University
Kingston, Canada; June 2005.
- **Citywide Nephrology Rounds**.

- “Treatment of Dyslipidemia in Chronic Kidney Disease.”
Vancouver General Hospital, University of British Columbia
Vancouver, Canada; April 2005.
- **Cardiology Rounds**
“Treatment of Dyslipidemia in Chronic Kidney Disease.”
Vancouver General Hospital, University of British Columbia
Vancouver, Canada; April 2005.
 - **Nephrology Grand Rounds.**
“Treatment of Dyslipidemia in Chronic Kidney Disease.”
Foothills Hospital, University of Calgary
Calgary, Canada; February 2005.
 - **Citywide Nephrology Rounds.**
“End-stage Renal Disease in Aboriginal People in the Prairie Provinces.”
Toronto General Hospital, University of Toronto
Toronto, Canada; January 2005.
 - **Department of Medicine Grand Rounds, Royal Alexandra Hospital.**
“Dyslipidemia as a Risk Factor for Progressive Kidney Failure.”
Edmonton, Canada; December 2004.
 - **Cardiology Grand Rounds, Royal Alexandra Hospital.**
“Does Treatment of Dyslipidemia Protect the Kidney as Well as the Heart?”
Edmonton, Canada; November 2004.
 - **Cardiology Grand Rounds, University of Alberta, Division of Cardiology.**
“Statins and Dyslipidemia in Chronic Kidney Disease.”
Edmonton, Canada; November 2004.
 - **American Society of Nephrology Post Graduate Education Course, 37th Renal Week**
“Lipids and Progression of Kidney Disease.”
St. Louis, USA; October 2004.
 - **Nephrology Grand Rounds, University of Saskatchewan.**
“Treatment of Dyslipidemia in Renal Insufficiency Patients.”
Saskatoon, Canada; October 2004.
 - **15th Annual Western Peritoneal Dialysis Days; University of Calgary, Department of Medicine.**
“What is (Not) Known About Cholesterol and PD Patients.”
Calgary, Canada; September 2004.
 - **Canadian Society of Nephrology, Annual Meeting.**
“Statins in Chronic Kidney Disease.”
Toronto, Canada; May 2004.
 - **Vanguard of Hemodialysis Conference.**
“Epidemiology of Vascular Access.”
“Screening Strategies for Native Vessel AV Fistulae.”
Guadalajara, Mexico; March 2004.
 - **Medical Grand Rounds; University of Alberta, Department of Medicine.**
“Dyslipidemia in Chronic Kidney Disease.”
Edmonton, Canada; September 2003.
 - **University of Manitoba, Division of Nephrology.**
“Diagnosing Subclinical Access Dysfunction in Native Vessel AV Fistulae.”
Winnipeg, Canada; September 2003.
 - **Alberta Nephrology Days (CME); University of Alberta, Division of Nephrology.**
“Cardiovascular Disease in Chronic Renal Failure.”
Kananaskis, Canada; May 2003.

- **Canadian Society of Nephrology**, Annual Meeting.
“Dyslipidemia in Kidney Disease.”
St. John’s, Canada; May 2003.
- **Nephrology Grand Rounds**, University of Alberta, Department of Medicine.
“Screening for Subclinical stenosis in Native Vessel Arteriovenous Fistulae.”
Edmonton, Canada; September 2001.
- **Nephrology Grand Rounds**, Foothills Health Sciences Center, University of Calgary
“Screening for Subclinical Stenosis in Native Vessel Arteriovenous Fistulae.”
Calgary, Canada; March 2001.
- **Canadian Society of Nephrology**, Annual Meeting.
“Research Training in Nephrology.”
Vancouver, Canada; March 2001.

Continuing Medical Education:

- “Protective Effects of Statins in Hypertension and Renal Disease.”
Boyle-McCauley Clinic; Edmonton, Canada; April 2005.
- “Renal Implications of Statin Therapy.”
Abbotsfield Clinic; Edmonton, Canada; February 2004.
- Citywide Family Medicine Rounds.
“Renal Implications of Statin Therapy.”
Lamont, Canada; October 2003.
- “Renal Implications of Statin Therapy.”
Edmonton, Canada; October 2003.
- “Renal Implications of Statin Therapy.”
Ft. McMurray, Canada; September 2003.”
- “Renal Implications of Statin Therapy.”
Allin Clinic; Edmonton, Canada; September 2003.

Local Presentations:

- **Nephrology Grand Rounds**; University of Alberta, Division of Nephrology.
“Geography and Health for Canadians with Kidney Disease.”
Edmonton, Canada; December 2006.
- **Nephrology Core Lecture Series**; University of Alberta, Division of Nephrology.
”HD Access and Access Monitoring”
Edmonton, Canada; September 2005.
- **Nephrology Core Lecture Series**; University of Alberta, Division of Nephrology.
“Water Treatment for Hemodialysis.”
Edmonton, Canada; September 2005.
- **Nephrology Core Lecture Series**; University of Alberta, Division of Nephrology.
“Reuse of Dialyzers.”
Edmonton, Canada; September 2005.
- **Nephrology Core Lecture Series**; University of Alberta, Division of Nephrology.
“Vascular Access Monitoring.”
Edmonton, Canada; August 2005.
- **Clinical Epidemiology Rounds**; University of Alberta, Department of Public Health.
“Dyslipidemia and Progression of Chronic Kidney Disease.”
Edmonton, Canada; March 2005.
- **Nephrology Lecture Series**; University of Alberta, Division of Nephrology.
“Vascular Access Monitoring.”
Edmonton, Canada; November 2004.
- **Research in Progress**; University of Alberta, Division of Nephrology.

- “Design of a Cohort Study in Kidney Disease.”
Edmonton, Canada; November 2004.
- **Nephrology Lecture Series (Critical Appraisal);** University of Alberta, Division of Nephrology.
“Practice Guidelines.”
Edmonton, Canada; May 2004.
 - **Nephrology Lecture Series;** University of Alberta, Division of Nephrology.
“Reuse of Dialyzers.”
Edmonton, Canada; May 2004.
 - **Nephrology Grand Rounds;** University of Alberta, Division of Nephrology.
“Opportunity Cost and Hemodialysis: The Case of Sevelamer.”
Edmonton, Canada; April 2004.
 - **Nephrology Lecture Series;** University of Alberta, Division of Nephrology.
“Water Treatment for Hemodialysis.”
Edmonton, Canada; March 2004.
 - **Clinical Epidemiology Rounds;** University of Alberta, Department of Public Health Medicine.
“Health Outcomes among Aboriginal People Treated for End-stage Renal Disease in the Prairie Provinces.”
Edmonton, Canada; February 2004.
 - **Nephrology Grand Rounds;** University of Alberta, Division of Nephrology.
“Hemodialysis and Opportunity Cost.”
Edmonton, Canada; April 2003.
 - **Nephrology Grand Rounds,** University of Alberta, Division of Nephrology.
“Cost Effectiveness of Erythropoietic Therapies in Hemodialysis Patients.”
Edmonton, Canada; December 2002.

Salary Awards

- **Alberta Heritage Foundation for Medical Research, Population Health Investigator Establishment Award Renewal (2006)**
Amount Awarded: \$65,853/annum; Term: Three years
- **Canadian Institutes for Health Research New Investigator Award (2005)**
Amount Awarded: \$173,964; Term: Three years
- **Alberta Heritage Foundation for Medical Research, Independent Award (Population Health Investigator Establishment Grant) (2003)**
Amount awarded (July 2003): \$150,000; Term: Three years.

Operating Grant Support (past five years):

Primary Investigator:

- **Canadian Institutes of Health Research/Abbott Laboratories (2008):**
“Genetic markers of risk in hemodialysis patients.”
M. Tonelli (PI), B. Hemmelgarn, J. Gill, R. Parekh, D. Emery, R. Thadhani, D. Friedman, K. Sekar, C. Chan, G. Block.
Amount awarded (July 2008): \$659,002 (CIHR); \$3,000,000 (Abbott); Term: 5 years
- **Canadian Institutes of Health Research (2008):**
“Role of residence location in the care of elderly Canadians with kidney failure.”
M. Tonelli (PI), S. Davison, J.S. Gill, B. Hemmelgarn, B. Manns, N. Pannu, N. Wiebe, K. Yeates.
Amount awarded (February 2008): \$652,880; Term: Five years.

- **Canadian Institutes of Health Research (2007):**
 “Trace element status in chronic hemodialysis patients”
M. Tonelli (PI), B. Culleton, S. Klarenbach, B. Hemmelgarn, B. Manns, K. Jindal, C. Field, G. Cembrowski, D. Holmes, N. Wiebe, K. Oseen, J. Gill
 Amount awarded (September 2007) \$992,811; Term: Five years
- **Canadian Agencies for Drugs and Technologies in Health (2007):**
 “Hematopoietic hormones in the treatment of anemia related to cancer.”
M. Tonelli (PI)
 Amount awarded (August 2007): \$115,282; Term: One year.
- **Center for D-Receptor Activation Research (2007)**
 “Vitamin D status as a determinant of mortality in remote-dwelling Canadian dialysis patients”
M. Tonelli (PI)
 Amount awarded (July 2007) \$83,766; Term: One year.
- **Heart and Stroke Foundation of Canada GIA (2007):**
 "Relation between residence location, care quality and cardiovascular events in people with Diabetes Mellitus and Kidney disease."
M. Tonelli (PI), B. Culleton, K. Jindal
 Amount awarded (July 2007) \$137,746; Term: Three years.
- **Kidney Foundation of Canada (2007):**
 “Factors associated with primary non-function and unassisted primary patency in patients with arteriovenous fistulae (AVF)”
M. Tonelli (PI)
 Amount awarded (July 2007) \$100,000; Term: Two years.
- **Canadian Institutes of Health Research (2007)**
 “Research synthesis: evidence-based management of waiting lists for kidney transplantation”
M. Tonelli (PI), S. Klarenbach, G. Knoll, J. Gill
 Amount awarded (July 2007) \$88,292; Term: One year.
- **Canadian Agencies for Drugs and Technologies in Health (2007):**
 “A systematic review and economic evaluation of hematopoietic therapies in patients with chronic renal failure.”
M. Tonelli (PI)
 Amount awarded (January 2007): \$119,525; Term: One year.
- **University Hospital Foundation Medical Research Grant Competition (2006):**
 "Influence of Deficiency and Excess of Trace Elements on Outcomes in Hemodialysis Patients"
M. Tonelli (PI)
 Amount awarded (January 2007) \$25,000; Term: One year.
- **Pfizer Canada (2006):**
 “Geographic information systems (GIS) for vascular risk reductions in Albertans with chronic kidney disease (CKD).”
M. Tonelli (PI)
 Amount awarded (November 2006): \$169,800; Term: Three years.

- **Canadian Agencies for Drugs and Technologies in Health (2006):**
 “A systematic review and economic evaluation of continuous renal replacement therapy in patients with acute renal failure.”
M. Tonelli (PI)
 Amount awarded (June 2006): \$96,025; Term: One year.
- **University Hospital Foundation Medical Research Grant Competition (2005):**
 “Pulse Wave Velocity as a Predictor of Primary Non-Function in Arteriovenous Fistulae Used for Hemodialysis”
M. Tonelli (PI), N. Pannu, S. Shurraw
 Amount awarded (January 2006) \$22,250; Term: One year.
- **International Partnership Fund Committee (2005)**
 “A Program Aimed at the Early Detection and Treatment of Diabetes and Chronic Kidney Disease in Jalisco.”
M. Tonelli (PI).
 Amount awarded (April 2005): \$4,920; Term: One year.
- **Northern Alberta Renal Program Research Fund (2005)**
 “Determination of the Primary Non-function Rate in AVF Created in the Northern Alberta Renal Program.”
M. Tonelli (PI), C. Johnston, G. Winkelaar, S. Duggan.
 Amount awarded (March 2005): \$50,000; Term: One year.
- **Canadian Institutes of Health Research Operating Grant Competition (2005)**
 “The Role of Place and Relocation in the Care of Canadians with End-stage Renal Disease.”
M. Tonelli (PI), S. Bertazzon, B.F. Culleton, J.S. Gill, B. Hemmelgarn, B. J. Manns, A. Senthilselvan.
 Amount awarded (February 2005): \$173,964; Term: Three years.
- **University Hospital Foundation Medical Research Grant Competition (2005)**
 “A Pilot Study to Develop Methodology for the Conduct of a Prospective COHORT Study of Incident Dialysis Patients in Alberta (Alberta Kidney Disease COHORT Study).”
M. Tonelli (PI).
 Amount awarded (December 2004): \$24,960; Term: One year.
- **Alberta Heritage Foundation for Medical Research, Health Research Fund Competition (September 2003)**
 “Electronic Decision Support for Improving the Care of Hemodialysis Patients in Alberta.”
M. Tonelli (PI), T. Fox, S. Gourishankar, S. Klarenbach, K. McLaughlin, G. Mortis.
 Amount awarded (October 2004): \$199,968; Term: Two years.
- **University Hospital Foundation Medical Research Grant Competition (2004)**
 “Relation between Socioeconomic Status and Geographical Location on Health Outcomes in Canadians Requiring Renal Replacement Therapy.”
M. Tonelli (PI).
 Amount awarded (December 2003): \$8,500; Term: One year.
- **University Hospital Foundation Medical Research (2003) Competition**
 “Access Flow Measurements to Predict Primary Non-function of Native Vessel Arteriovenous Fistulae for Hemodialysis.”

M. Tonelli (PI), S. Caldwell.

Amount awarded (December 2002): \$23,500; Term: One year.

Co-Investigator:

- **Canadian Institutes of Health Research (2008):**
“Characterizing the dying experience and end-of-life care need for patients with chronic kidney disease.”
S. Davison (PI), S. Klarenbach, **M. Tonelli**
- **Canadian Institutes of Health Research (2008)**
“Progression and management of chronic kidney disease among First Nations People”
B. Hemmelgarn (PI), S. Ahmed, L. Crowshoe, P. Faris, W. Ghali, B. Manns, **M. Tonelli.**
Amount awarded (January 2008): \$158,000; Term: Two years.
- **International Society of Nephrology COMGAN (2007)**
“Data Collection and Surveillance of Prevention Programs in Emerging Countries: The Kidney Disease Data Center (KDDC) program”
G. Remuzzi (PI), N. Perico, A. Remuzzi, B. Ene-Iordache, **M. Tonelli**, P. Ruggenti.
Amount awarded (2007): \$20,000US; Term: Three years.
- **Canadian Institutes of Health Research Operating Grant (2005)**
“Access to Kidney Transplantation in British Columbia and Alberta”
J. Gill (PI), **M. Tonelli**, S. Gourishankar, B. Manns, K. McLaughlin.
Amount awarded (July 2005):\$129,000; Term: Five years.
- **Canadian Institutes of Health Research Operating Grant (2005)**
“Chronic Kidney Disease among First Nations People in Alberta: Prevalence, Progression, and Access to Care.”
B. Hemmelgarn (PI), S. Bertazzon, L. F. Crowshoe, B. F. Culleton, W.A. Ghali, D. M. Lentjes, B. Manns, L. Svenson, **M. Tonelli.**
Amount awarded (July 2005): \$208,545; Term: Three years.
- **Alberta Heritage Foundation for Medical Research (2004)**
“Optimizing Prevention of Vascular Disease in Alberta: A Program of Health Outcomes Research.”
F. McAlister (PI), S. Majumdar, **M. Tonelli.**
Amount awarded (July 2004): \$870,000; Term: Three years.
- **University Health Network/Canadian Institutes for Health Research (2004)**
“Fish Oil Stenosis in Hemodialysis Grafts (FISH) Study.”
C. Lok (PI), L. Moist, M. Oliver, R. Richardson, **M. Tonelli.**
Amount awarded (July 2004): \$319,134 cash flow basis (U of A Center); Term: Three years.
- **Alberta Heritage Foundation for Medical Research (2004)**
“Chronic Kidney Disease Among the Elderly in Alberta: Prevalence and Access to Care.”
B. Hemmelgarn (PI), B. Manns, B. Culleton, **M. Tonelli.**
Amount awarded (July 2004): \$98,572. Term: Two years.
- **Amgen Canada Inc (2004)**
“A computerized Chronic Kidney Disease Network: A Database for Accessing Care and

Determining Progression.”

K. Taub (PI), **M. Tonelli**.

Amount awarded (April 2004): \$480,000; Term: Three years.

- **Canadian Institutes of Health Research/Memorial University (2004).**
“Canadian Prevention of Renal and Cardiovascular Endpoints Trial (CAN-PREVENT).”
Amount awarded: \$10,000 (cash transfer), Term: one year; initiated: February 2004.
- **Kidney Foundation of Canada (2003)**
“An Economic Evaluation of Improving Dialysis Adequacy in Large Hemodialysis Patients.”
B. Manns (PI), **M. Tonelli**, K. Taub, J. Johnson, C. Donaldson.
Amount awarded (May 2003): \$93,000; Term: Two years.

Reviewing Activities:

Editorial Positions:

- Section Editor, Seminars in Dialysis
Term (August 2008): Three years
- Associate Editor, American Journal of Kidney Diseases
Term (September 2006): Three years.
- Associate Editor, Journal of Nephrology
Term (December 2006): Three years.

Acting Editor in Chief

- American Journal of Kidney Diseases
Manuscript 06-011631, 2006
Manuscript 07-0935, 2007
Manuscript 07-01043, 2007

Editorial Boards:

- Journal of the American Society of Nephrology (JASN).
Term (July 2005): Three years.

Peer Reviewed Journals:

- American Journal of Clinical Nutrition
- American Journal of Kidney Disease
- American Journal of Transplantation
- Annals of Internal Medicine
- Archives of Internal Medicine
- Arteriosclerosis, Thrombosis, and Vascular Biology
- Canadian Medical Association Journal
- Clinical Journal of the American Society of Nephrology (cJASN)
- Circulation
- Cochrane Library - Cochrane Renal Group
- Critical Care Medicine
- Journal of the American Medical Association (JAMA)
- Journal of the American Society of Nephrology (JASN)
- Kidney and Blood Pressure Research
- Kidney International

- The Lancet
- Nature Clinical Practice Nephrology
- Nephrology, Dialysis, and Transplantation

Grant Applications:

- **Canadian Institutes of Health Research (CIHR)**, Doctoral Research Award A and B (DRA/DRB) Committees 2006-2008.
- **National Institutes of Health, National Institutes of Diabetes and Digestive and Kidney Diseases (NIH/NIDDK)**, Special Emphasis Grant Panel 2006.
- **National Institutes of Health, National Institutes of Diabetes and Digestive and Kidney Diseases (NIH/NIDDK)**, R21/R33 Grant Review Panel 2005-2006.
- **Canadian Institutes of Health Research**, Operating Grant Reviewer 2004.
- **Kidney Foundation of Canada**, Biomedical Fellowship and Scholarship Review Panel 2003-2006.
- **Kidney Foundation of Canada**, Biomedical Grant Reviewer 2003, 2005-2006.
- **Center for D-Receptor Activation Research**, Grant Reviewer 2005-2006.

Scientific:

- **Province of Alberta, Minister's Expert Committee on Drug Evaluation and Therapeutics**, Member (2006-).
- **Canadian Agency for Drugs and Technology in Health (formerly Canadian Coordinating Office for Health Technology Assessment)**, Health Technology Clinician-Expert Reviewer (2003-).
Health Technology External Systematic Reviewer (2004-2005).
Health Technology External Pharmacoeconomic Reviewer (2005-).
- **Capital Health Drug Utilization Advisory Subcommittee**, 2006.
- **Canadian Organ Replacement Registry Research Committee (CORR)**, Annual Report Reviewer 2006, 2007.

Academic:

- **Adjudicator. Abstract reviewer.** Canadian Society of Nephrology Annual Meeting, 2008.
- **Adjudicator. Abstract reviewer**, "Clinical Nephrology: Epidemiology, Outcomes, Clinical Trials, Health Services Research." American Society of Nephrology Annual Meeting, 2004, 2005, 2006, 2007.
- **Abstract Review. Category Chair.** "Dialysis, Epidemiology, Health Services Research and Ethics." American Society of Nephrology Annual Meeting Program Committee, 2004.
- **Abstract Review Chair. Section chair**, "Clinical Nephrology: Hemodialysis Epidemiology, Outcomes". American Society of Nephrology Annual Meeting, 2004.
- **Adjudicator. Abstract reviewer**, Core Internal Medicine Resident and Subspecialty Residents; University of Alberta Department of Medicine Research Day. 2005, 2007.
- **Adjudicator. Abstract reviewer**, University of Alberta Cardiac Sciences Research Day. 2007.

Bibliography

Peer-Reviewed Publications:

1. Rucker D, **Tonelli M.** *Cardiovascular risk and management in chronic kidney disease.* Nature Clin Prac Nephrol 2008 (in press)

2. Yeates K, Wiebe N, Gill J, Sima C, Schaubel D, Holland D, Hemmelgarn B, **Tonelli M**. *A comparison of outcomes in renal transplantation among black and white patients in Canada*. J Am Soc Nephrol 2008 (in press)
3. **Tonelli M**. *Statins for slowing kidney disease progression: an as-yet unproven indication*. Am J Kidney Dis 2008 (in press)
4. Gao S, Manns B, Culleton B, **Tonelli M**, Quan H, Crowshoe L, Ghali W, Svenson L, Ahmed S, Hemmelgarn B. *Access to health care for status Aboriginal People with chronic kidney disease*. CMAJ 2008 (in press).
5. Rucker D, **Tonelli M**, Coles M, Yoo S, Young K, McMahon A. *Vitamin D Insufficiency And Treatment With Oral Vitamin D3 In Northern-Dwelling Patients With Chronic Kidney Disease*. J Nephrol 2008 (in press)
6. Levin A, Hemmelgarn B, Culleton B, Tobe S, McFarlane P, Ruzicka M, Burns K, Manns B, White C, Madore F, Moist L, Klarenbach S, Barrett B, Foley R, Jindal K, Senior P, Pannu N, Shurraw S, Akbari A, Cohn A, Reslerova M, Deved V, Mendelssohn D, Nesrallah G, Kappel J, **Tonelli M**. *Guidelines for the management of chronic kidney disease: 2008*. CMAJ 2008 (in press).
7. Gutiérrez O, Tamez H, Bhan I, Zazra J, **Tonelli M**, Wolf M, Januzzi J, Chang Y, Thadhani R. *N-terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) Concentrations in Hemodialysis Patients: Prognostic Value of Baseline and Follow-up Measurements* Clin Chem. 2008 Jun 6. [Epub ahead of print]
8. Ahmed S, Culleton B, **Tonelli M**, Klarenbach S, Macrae J, Zhang J, Hemmelgarn B.. *Oral estrogen therapy in postmenopausal women is associated with loss of kidney function*. Kidney Int. 2008 May 21. [Epub ahead of print]
9. **Tonelli M**. *Randomized trials in hemodialysis patients: time to step up to the plate*. JAMA. 2008 May 14;299(18):2205-7
10. James M, Conley J, **Tonelli M**, Manns B, MacRae J, Hemmelgarn B; Alberta Kidney Disease Network. *Meta-analysis: antibiotics for prophylaxis against hemodialysis catheter-related infections*. Ann Intern Med. 2008 Apr 15;148(8):596-605.
11. Wang W, **Tonelli M**, Hemmelgarn B, Gao S, Johnson J, Taub K, Manns B; Alberta Kidney Disease Network. *The effect of increasing dialysis dose in overweight hemodialysis patients on quality of life: a 6-week randomized crossover trial*. Am J Kidney Dis. 2008 May;51(5):796-803. Epub 2008 Apr 2.
12. **Tonelli M**, James M, Wiebe N, Jindal K, Hemmelgarn B; Alberta Kidney Disease Network. *Ultrasound monitoring to detect access stenosis in hemodialysis patients: a systematic review*. Am J Kidney Dis. 2008 Apr;51(4):630-40. Epub 2008 Mar 6.
13. Mathew A, Devereaux P, O'Hare A, **Tonelli M**, Thiessen-Philbrook H, Nevis I, Iansavichus A, Garg A. *Chronic kidney disease and postoperative mortality: a systematic review and meta-analysis*. Kidney Int. 2008 May;73(9):1069-81. Epub 2008 Feb 20.
14. Pannu N, Klarenbach S, Wiebe N, Manns B, **Tonelli M**; Alberta Kidney Disease Network. *Renal replacement therapy in patients with acute renal failure: a systematic review*. JAMA. 2008 Feb 20; 299(7):793-805.
15. Al-Ghonaim M, Manns B, Hirsch D, Gao Z, **Tonelli M**; for the Alberta Kidney Disease Network. *Relation between access blood flow and mortality in chronic hemodialysis patients*. Clin J Am Soc Nephrol. Epub 2008 Jan 30.
16. **Tonelli M**, Sacks F, Arnold M, Moye L, Davis B, Pfeffer M; for the Cholesterol and Recurrent Events (CARE) Trial Investigators. *Relation between red blood cell distribution width and cardiovascular event rate in people with coronary disease*. Circulation. 2008 Jan 15; 117(2):163-8. Epub 2008 Jan 2.
17. **Tonelli M**. *Vitamin D in patients with chronic kidney disease: nothing new under the sun*. Ann Intern Med. 2007 Dec 18; 147(12):880-1.

18. Wang W, Murphy B, Yilmaz S, **Tonelli M**, Macrae J, Manns B. *Comorbidities do not influence primary fistula success in incident hemodialysis patients: a prospective study.* Clin J Am Soc Nephrol. 2008 Jan; 3(1):78-84. Epub 2007 Nov 7.
19. **Tonelli M**, Manns B, Culleton B, Klarenbach S, Hemmelgarn B, Wiebe N, Gill JS; Alberta Kidney Disease Network. *Association between proximity to attending nephrologist and mortality among patients receiving hemodialysis.* CMAJ. 2007 Oct 23; 177(9):1039-44.
20. Gao S, Manns B, Culleton B, **Tonelli M**, Quan H, Crowshoe L, Ghali W, Svenson L, Hemmelgarn B; Alberta Kidney Disease Network. *Prevalence of chronic kidney disease and survival among aboriginal people.* J Am Soc Nephrol. 2007 Nov; 18(11):2953-9. Epub 2007 Oct 17.
21. **Tonelli M**, Wiebe N, Culleton B, Lee H, Klarenbach S, Shrive F, Manns B; Alberta Kidney Disease Network. *Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients.* Nephrol Dial Transplant. 2007 Oct; 22(10):2856-66.
22. Culleton B, Walsh M, Klarenbach S, Mortis G, Scott-Douglas N, Quinn R, **Tonelli M**, Donnell S, Friedrich M, Kumar A, Mahallati H, Hemmelgarn B, Manns B. *Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial.* JAMA. 2007 Sep 19; 298(11):1291-9.
23. **Tonelli M**, Hemmelgarn B, Gill JS, Chou S, Culleton B, Klarenbach S, Manns B, Wiebe N, Gourishankar S. *Patient and allograft survival of Indo Asian and East Asian dialysis patients treated in Canada.* Kidney Int. 2007 Aug; 72(4):499-504.
24. Wolf M, Shah A, Gutierrez O, Ankers E, Monroy M, Tamez H, Steele D, Chang Y, Camargo C Jr, **Tonelli M**, Thadhani R. *Vitamin D levels and early mortality among incident hemodialysis patients.* Kidney Int. 2007 Oct; 72(8):1004-13. Epub 2007 Aug 8.
25. Gill J, Hussain S, Rose C, Hariharan S, **Tonelli M**. *Access to Kidney Transplantation among Patients Insured by the United States Department of Veterans Affairs.* J Am Soc Nephrol. 2007 Sep; 18(9):2592-9. Epub 2007 Aug 8.
26. Walsh M, James M, Jayne D, **Tonelli M**, Manns B, Hemmelgarn B. *Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis.* Clin J Am Soc Nephrol. 2007 Sep; 2(5):968-75. Epub 2007 Aug 8.
27. **Tonelli M**, Hemmelgarn B, Culleton B, Klarenbach S, Gill JS, Wiebe N, Manns B. *Mortality of Canadians treated by peritoneal dialysis in remote locations.* Kidney Int. 2007 Oct; 72(8):1023-8. Epub 2007 Jul 18.
28. Manns B, Klarenbach S, Lee H, Culleton B, Shrive F, **Tonelli M**. *Economic evaluation of sevelamer in patients with end-stage renal disease.* Nephrol Dial Transplant. 2007 Oct; 22(10):2867-78. Epub 2007 Jun 25.
29. Garcia-Garcia G, Briseno-Renteria G, Luquin-Arellano VH, Gao Z, Gill J, **Tonelli M**. *Survival among patients with kidney failure in Jalisco, Mexico.* J Am Soc Nephrol. 2007 Jun; 18(6):1922-7. Epub 2007 May 9.
30. Lok C, Allon M, Donnelly S, Dorval M, Hemmelgarn B, Moist L, Oliver M, **Tonelli M**, Stanley K. *Design of the fish oil inhibition of stenosis in hemodialysis grafts (FISH) study.* Clin Trials. 2007; 4(4):357-67.
31. Keltai M, **Tonelli M**, Mann J, Sitkei E, Lewis B, Hawken S, Mehta S, Yusuf S. *Renal function and outcomes in acute coronary syndrome: impact of clopidogrel.* Eur J Cardiovasc Prev Rehabil. 2007 Apr; 14(2): 312-8.
32. Walsh M, **Tonelli M**, Jayne D, Manns B. *Surrogate end points in clinical trials: the case of anti-neutrophil cytoplasm antibody-associated vasculitis.* J Nephrol 2007 Mar-Apr; 20(2):119-29.
33. Gooch K, Culleton B, Manns B, Zhang J, Alfonso, Frank C, **Tonelli M**, Klarenbach S, Hemmelgarn B. *Non-steroidal anti-inflammatory drug use and progression of chronic kidney disease.* Am J Med. 2007 Mar; 120(3):e1-7.

34. Hemmelgarn B, Manns B, Zhang J, **Tonelli M**, Klarenbach S, Walsh M, Culleton B; for the Alberta Kidney Disease Network. *Association between Multidisciplinary Care and Survival for Elderly Patients with Chronic Kidney Disease*. JASN 2007 Mar; 18(3): 993-9. Epub 2007 Jan 31.
35. Gill JS, Rose C, Pereira B, **Tonelli M**. *The Importance Of Transitions Between Dialysis and Transplantation in the Care of End Stage Renal Disease Patients*. Kidney Int. 2007 Mar; 71(5):442-7. Epub 2007 Jan 17.
36. **Tonelli M**. *Should chronic kidney disease be a coronary heart disease risk equivalent?* Am J Kidney Dis. 2007 Jan; 49(1):8-11.
37. Hemmelgarn B, Chou S, Wiebe N, Culleton B, Manns B, Klarenbach S, Khan N, Gourishankar S, Yeates K, Gill JS, **Tonelli M**. *Differences in use of peritoneal dialysis and survival among East Asian, Indo-Asian, and white ESRD patients in Canada*. Am J Kidney Dis. 2006 Dec; 48(6):964-71.
38. Shurraw S, **Tonelli M**. *Statins for treatment of dyslipidemia in chronic kidney disease*. Perit Dial Int. 2006 Sep-Oct; 26(5):523-39.
39. **Tonelli M**, Klarenbach S, Manns B, Culleton B, Hemmelgarn B, Bertazzon S, Wiebe N, Gill JS; Alberta Kidney Disease Network. *Residence location and likelihood of kidney transplantation*. CMAJ. 2006 Aug 29; 175(5):478-82.
40. **Tonelli M**. *Do statins protect the kidney by reducing proteinuria?* Ann Intern Med. 2006 Jul 18; 145(2):147-9.
41. Manns B, Owen W Jr, Winkelmayr W, Devereaux P, **Tonelli M**. *Surrogate markers in clinical studies: problems solved or created?* Am J Kidney Dis. 2006 Jul; 48(1):159-66.
42. Sandhu S, Wiebe N, Fried L, **Tonelli M**. *Statins for improving renal outcomes: a meta-analysis*. J Am Soc Nephrol. 2006 Jul; 17(7):2006-16.
43. **Tonelli M**, Wiebe N, Culleton B, House A, Rabbat C, Fok M, McAlister F., Garg A. *Chronic kidney disease and mortality risk: a systematic review*. JASN. 2006 Jul; 17(7):2034-47.
44. **Tonelli M**, Hemmelgarn B, Kim A, Bertazzon S, Klarenbach S, Manns B, Wiebe N, Culleton B, Gill JS. *Association between residence location and likelihood of kidney transplantation in Aboriginal patients treated with dialysis in Canada*. Kidney Int. 2006 Sep; 70(5):924-30. Epub 2006 Jun 21.
45. Pannu N, Wiebe N, **Tonelli M**; Alberta Kidney Disease Network. *Prophylaxis strategies for contrast-induced nephropathy*. JAMA. 2006 Jun 21; 295(23):2765-79.
46. **Tonelli M**, Jose P, Curhan G, Sacks F, Braunwald E, Pfeffer M. *Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: analysis of a previously conducted randomised trial*. BMJ. 2006 Jun 17; 332(7555):1426.
47. **Tonelli M**, Klarenbach S, Jindal K, Manns B; Alberta Kidney Disease Network. *Economic implications of screening strategies in arteriovenous fistulae*. Kidney Int. 2006 Jun; 69(12):2219-26.
48. **Tonelli M**, Klarenbach S, Jindal K, Manns B. *Economic Implications of Screening Strategies in Arteriovenous Fistulae*. Kidney Int. 2006 June; 69(12):2120-1.
49. Hemmelgarn B, Zhang J, Manns B, **Tonelli M**, Larsen E, Ghali W, Southern D, McLaughlin K, Mortis G, Culleton B. *Progression of kidney dysfunction in the community-dwelling elderly*. Kidney Int. 2006 Jun; 69(12):2155-61.
50. **Tonelli M**, Sacks F, Pfeffer M, Lopez-Jimenez F, Jhangri G, Curhan G. *Effect of pravastatin on blood pressure in people with cardiovascular disease*. J Hum Hypertens. 2006 Aug; 20(8):506-5. Epub 2006 Apr 20.
51. Klarenbach S, Pannu N, **Tonelli M**, Manns B. *Cost-effectiveness of hemofiltration to prevent contrast nephropathy in patients with chronic kidney disease*. Crit Care Med. 2006 Apr; 34(4):1044-51.
52. Pannu N, Jhangri G, **Tonelli M**. *Optimizing Dialysis Delivery in Tunneled Dialysis Catheters*. ASAIO Journal. 2006 March/April; 52(2):157-162.

53. Jindal K, Chan C, Deziel C, Hirsch D, Soroka S, **Tonelli M**, Culleton B; Canadian Society of Nephrology Committee for Clinical Practice Guidelines. *Hemodialysis clinical practice guidelines for the Canadian Society of Nephrology*. J Am Soc Nephrol. 2006 Mar; 17(3 Suppl 1):S1-27.
 - a. Jindal K, Chan C, Deziel C, Hirsch D, Soroka S, **Tonelli M**, Culleton BF. *CHAPTER 1: Hemodialysis Adequacy in Adults*. J Am Soc Nephrol. 2006 Mar; 17 Suppl 1:S4-7.
 - b. Jindal K, Chan C, Deziel C, Hirsch D, Soroka SD, **Tonelli M**, Culleton B. *CHAPTER 2: Management of Blood Pressure in Hemodialysis Patients*. J Am Soc Nephrol. 2006 Mar; 17 Suppl 1:S8-S10.
 - c. Jindal K, Chan C, Deziel C, Hirsch D, Soroka S, **Tonelli M**, Culleton B. *CHAPTER 3: Mineral Metabolism*. J Am Soc Nephrol. 2006 Mar; 17 Suppl 1:S11-5.
 - d. Jindal K, Chan C, Deziel C, Hirsch D, Soroka S, **Tonelli M**, Culleton B. *CHAPTER 4: Vascular Access*. J Am Soc Nephrol. 2006 Mar; 17 Suppl 1:S16-23.
 - e. Jindal K, Chan C, Deziel C, Hirsch D, Soroka S, **Tonelli M**, Culleton B. *CHAPTER 5: Frequent and Sustained Hemodialysis*. J Am Soc Nephrol. 2006 Mar; 17 Suppl 1:S24-7.
54. Walsh M, Manns B, Klarenbach S, Quinn R, **Tonelli M**, Culleton B. *The effects of nocturnal hemodialysis compared to conventional hemodialysis on change in left ventricular mass: Rationale and study design of a randomized controlled pilot study*. BMC Nephrol. 2006 Feb 22; 7(1):2.
55. Culleton B, Manns B, Zhang J, **Tonelli M**, Klarenbach S, Hemmelgarn B. *Impact of anemia on hospitalization and mortality in older adults*. Blood. 2006 May 15; 107(10):3841-6. Epub 2006 Jan 10.
56. Chou S, **Tonelli M**, Bradley J, Gourishankar S, Hemmelgarn B; for the Alberta Kidney Disease Network. *Quality of Care among Aboriginal Hemodialysis Patients*. Clin J Am Soc Nephrol. 2006 Jan; 1(1):58-63.
57. **Tonelli M**, Chou S, Gourishankar S, Jhangri G, Bradley J, Hemmelgarn B. *Wait-listing for kidney transplantation among Aboriginal hemodialysis patients*. Am J Kidney Dis. 2005 Dec; 46(6):1117-23.
58. **Tonelli M**, Keech A, Shepherd J, Sacks F, Tonkin A, Packard C, Pfeffer M, Simes J, Isles C, Furberg C, West M, Craven T, Curhan G. *Effect of pravastatin in people with diabetes and chronic kidney disease*. J Am Soc Nephrol. 2005 Dec; 16(12):3748-54.
59. Khan N, Hemmelgarn B, **Tonelli M**, Thompson C, Levin A. *Prognostic value of troponin T and I among asymptomatic patients with end-stage renal disease: a meta-analysis*. Circulation. 2005 Nov 15; 112(20):3088-96.
60. Garg A, **Tonelli M**. *The tension between E-health innovation and E-evaluation*. Arch Intern Med. 2005 Nov 14; 165(20):2329-30.
61. **Tonelli M**, Klarenbach S, Jindal K, Harries S, Zuidema S, Caldwell S, Pannu N. *Access flow in arteriovenous accesses by optodilutional and ultrasound dilution methods*. Am J Kidney Dis. 2005 Nov; 46(5):933-7.
62. **Tonelli M**, Sacks F, Pfeffer M, Gao Z, Gurhan G. *Relation between Serum Phosphate Level and Cardiovascular Event Rate in People with Coronary Disease*. Circulation. 2005 Nov; 68(5):2345-51.
63. Gill J, **Tonelli M**, Kiberd B, Johnson N, Pereira B. *The Impact of Waiting Time and Comorbid Conditions on the Survival Benefit of Kidney Transplantation*. Kidney Int. 2005 Nov; 68(5):2345-51.
64. Manlucu J, **Tonelli M**, Ray J, Papaioannou A, Youssef G, Thiessen H, Holbrook A, Garg A. *Dose Reducing H2 Receptor Antagonists in the Presence of Low Glomerular Filtration Rate: A Systematic Review of the Evidence*. Nephrol Dial Transplant. 2005 Nov; 20(11):2376-2384.

65. **Tonelli M**, Sacks F, Pfeffer M, Jhangri G, Curhan G. *Cholesterol and Recurrent Events (CARE) Trial Investigators, Biomarkers of Inflammation and Progression of Chronic Kidney Disease*. *Kidney Int*. 2005 July; 68(1):237-45.
66. **Tonelli M**, Isles C, Craven T, Tonkin A, Pfeffer M, Shepherd J, Sacks F, Furberg C, Cobbe S, Simes J, West M, Packard C, Curhan G. *Effect of Pravastatin on the Rate of Kidney Function Loss in People With or At Risk for Coronary Disease*. *Circulation*. 2005 July 12; 112(2):171-8.
67. Mahoney B, Smith, W, Lo D, Tsoi K, **Tonelli M**, Clase C. *Emergency Interventions for Hyperkalemia*. *Cochrane Database Syst Rev*. 2005 18;(2)CD003235.
68. Walsh M, Culleton B, **Tonelli M**, Yeates K, Gill JS. *A Systematic Review of the Effect of Nocturnal Hemodialysis on Blood Pressure, Left Ventricular Hypertrophy, Anemia, Mineral Metabolism, and Health-related Quality of Life*. *Kidney Int*. 2005 Apr; 67(4):1500-8.
69. **Tonelli M**, Hemmelgarn B, Manns B, Davison S, Bohm C, Gourishankar S, Pylypchuk G, Yeates K, Gill JS. *Use and Outcomes of Peritoneal Dialysis among Aboriginal People in Canada*. *J Am Soc Nephrol*. 2005 Feb;16(2):482-8.
70. Manns B, **Tonelli M**, Yilmaz S, Lee H, Laupland K, Klarenbach S, Radkevich V, Murphy B. *Establishment and Maintenance of Vascular Access in Incident Hemodialysis Patients: A Prospective Cost Analysis*. *J Am Soc Nephrol*. 2005 Jan; 16(1)201-9.
71. **Tonelli M**, Collins D, Robins S, Bloomfield H, Curhan G. *Effect of Gemfibrozil on Change in Renal Function in Men with Moderate Chronic Renal Insufficiency and Coronary Disease*. *Am J Kidney Dis*. 2004 Nov; 44(5):832-9.
72. Gourishankar S, Jhangri G, **Tonelli M**, Wales L, Cockfield S. *Development of Diabetes Mellitus Following Kidney Transplantation: A Canadian Experience*. *Am J Transplant*. 2004 Nov; 4(11):1876-82.
73. Ezekowitz J, McAlister F, Humphries K, Norris C, **Tonelli M**, Ghali W, Knudtson M; APPROACH Investigators. *The Association among Renal Insufficiency, Pharmacotherapy, and Outcomes in 6,427 Patients with Heart Failure and Coronary Artery Disease*. *J Am Coll Cardiol*. 2004 Oct 19; 44(8):1587-92.
74. **Tonelli M**, Hirsch D, Chan C, Marrayatt J, Mossop P, Wile C, Jindal K. *Factors Associated with Access Blood Flow in Native Vessel Arteriovenous Fistulae*. *Nephrol Dial Transplant*. 2004 Oct; 19(10):2559-63.
75. Rapchuk I, Rabuka S, **Tonelli M**. *Perioperative Use of Beta-blockers among Suitable Candidates Remains Low: Experience of a Single Canadian Tertiary Institution*. *Can J Anaesth*. 2004 Oct; 51(8):761-7.
76. Gill J, **Tonelli M**, Johnson M, Pereira B. *Why do Preemptive Transplant Recipients Have an Allograft Survival Advantage?* *Transplantation*. 2004 Sep 27; 78(6)873-9.
77. **Tonelli M**, Isles C, Curhan G, Tonkin A, Pfeffer M, Shepherd J, Sacks F, Furberg C, Cobbe S, Simes J, Craven T, West M. *Effect of Pravastatin on Cardiovascular Events in People with Chronic Kidney Disease*. *Circulation*. 2004 Sep 21; 110(12):1557-63.
78. **Tonelli M**, Hemmelgarn B, Manns B, Pylypchuk G, Bohm C, Yeates K, Gourishankar S, Gill J. *Death and Renal Transplantation in Aboriginal People Receiving Dialysis*. *CMAJ*. 2004 Sep 14; 171(6):577-82.
79. **Tonelli M**, Collins D, Robins A, Bloomfield H, Curhan G; Veterans' Affairs High-Density Lipoprotein Intervention Trial (VA-HIT). *Gemfibrozil for Secondary Prevention of Cardiovascular Events in Mild to Moderate Chronic Renal Insufficiency*. *Kidney Int*. 2004 Sep; 66(3):1123-1130.
80. Manns B, Stevens L, Miskulin D, Owen W Jr., Winkelmayr W, **Tonelli M**. *Systematic Review of Sevelamer in ESRD and an Analysis of its Potential Economic Impact in Canada and the United States*. *Kidney Int*. 2004 Sep; 66(3):1239-47.
81. Pannu N, Manns B, **Tonelli M**. *Systematic Review of the Impact on N-acetylcysteine on Contrast Nephropathy*. *Kidney Int*. 2004 Apr; 65(4):1366-1374.

82. McAlister F, Ezekowitz J, **Tonelli M**, Armstrong P. *Renal Insufficiency and Heart Failure: Prognostic and Therapeutic Implications from a Prospective Cohort Study*. *Circulation*. 2004 Mar 2; 109(8):1004-9.
83. Gill JS, **Tonelli M**, Mix C, Pereira P. *The Effect Of Maintenance Immunosuppression Medication On The Change In Kidney Allograft Function*. *Kidney Int*. 2004 Feb; 65(2):692-9.
84. **Tonelli M**, Dymond C, Gourishankar S, Jindal K. *Extended Reuse of Polysulfone Hemodialysis Membranes Using Citric Acid and Heat*. *ASAIO Journal*. 2004 Jan/Feb; 50(1):98-101.
85. **Tonelli M**, Jhangri G, Hirsch D, Marryatt J, Mossop P, Wile C, Jindal K. *Best Threshold for Diagnosis of Stenosis or Thrombosis within Six Months of Access Flow Measurement in Arteriovenous Fistulae*. *J Am Soc Nephrol*. 2003 Dec; 14(12):3264-9.
86. **Tonelli M**, Winkelmayer W, Jindal K, Owen W, Manns B. *The Cost Effectiveness of Maintaining Higher Hemoglobin Targets with Erythropoietin in Hemodialysis Patients*. *Kidney Int*. 2003 Jul; 64(1):295-304.
87. **Tonelli M**, Moye L, Sacks G, Cole T, Curhan G. *Effect of Pravastatin on Loss of Renal Function in People with Moderate Chronic Renal Insufficiency and Cardiovascular Disease*. *J Am Soc Nephrol*. 2003 Jun; 14(6):1605-13.
88. Gill JS, **Tonelli M**, Mix C, Pereira B. *Change in Allograft Function after Kidney Transplantation*. *J Am Soc Nephrol*. 2003 Jun; 14(6):1636-42.
89. Manns B, Doig C, Lee H, Dean S, **Tonelli M**, Johnson D, Donaldson C. *The Cost of Acute Renal Failure Requiring Dialysis in the Intensive Care Unit. The Clinical and Resource Implications of Renal Recovery*. *Crit Care Med*. 2003 Feb; 31(2):449-55.
90. **Tonelli M**, Moye L, Sacks F, Kiberd B, Curhan G. *Pravastatin for Secondary Prevention of Cardiovascular Events in Persons with Mild Chronic Renal Insufficiency*. *Ann Intern Med*. 2003 Jan 21; 138(2):98-104.
91. **Tonelli M**, Hirsch D, Clark T, Wile C, Mossop P, Marryatt J, Jindal K. *Access Flow Monitoring In Patients with Native Vessel Arteriovenous Fistulae and Previous Angioplasty*. *J Am Soc Nephrol*. 2002 Dec; 13(12):2969-73.
92. **Tonelli M**, Manns B, Feller-Kopman D. *Acute Renal Failure in the Intensive Care Unit: A Systematic Review of the Impact of Dialytic Modality on Mortality and Renal Recovery*. *Am J Kidney Dis*. 2002 Nov; 40(5):875-85.
93. **Tonelli M**, Astephen P, Andreou P, Beed S, Lundrigan P, Jindal K. *Blood Volume Monitoring In Intermittent Hemodialysis for Acute Renal Failure*. *Kidney Int*. 2002 Sept; 62(3):1075-80.
94. **Tonelli M**, Gill J, Pandeya S, Bohm C, Levin A, Kiberd B. *Barriers to Blood Pressure Control and Angiotensin Enzyme Inhibitor Use in Canadian Patients with Chronic Renal Insufficiency*. *Nephrol Dial Trans*. 2002 Aug; 17(8):1426-1433.
95. **Tonelli M**, Gill J, Pandeya S, Bohm C, Levin A, Kiberd B. *Slowing the Progression of Chronic Renal Insufficiency*. *CMAJ*. 2002 Apr; 166(7):906-7.
96. Thadhani R, Wolf M, West M, **Tonelli M**, Ruthazer R, Pastores G, Obrador G. *Patients with Fabry Disease on Dialysis in the United States*. *Kidney Int*. 2002 Jan; 61(1):249-255.
97. **Tonelli M**, Jindal K, Hirsch D, Taylor S, Kane C, Henbrey S. *Screening for Sub-Clinical Stenosis in Native Vessel Arteriovenous Fistulae*. *J Am Soc Nephrol*. 2001 Aug; 12(8):1729-33.
98. **Tonelli M**, Gill J, Pandeya S, Bohm C, Levin A, Kiberd B. *Cardiac Risk Factors and Use of Cardioprotective Medications in Patients with Chronic Renal Insufficiency*. *Am J Kidney Dis*. 2001 Mar; 37(3):484-9.
99. **Tonelli M**, Gill J, Blake P, Muirhead N. *Predictors of Erythropoietin Requirements in Chronic Hemodialysis Patients*. *ASAIO Journal*. 2001 Jan-Feb; 47(1):82-5.
100. **Tonelli M**, Muirhead N. *Access Type as a Predictor of Dialysis Adequacy in Chronic Hemodialysis Patients*. *ASAIO Journal*. 2000 May-Jun; 46(3):279-82.

Peer Reviewed Technology Reports

101. **Tonelli M**, Klarenbach S, Wiebe N, Shrive F, Hemmelgarn B, Manns B. *Erythropoiesis-stimulating agents for anemia of chronic kidney disease: systematic review and economic evaluation*. [Technology report number 106] (peer reviewed). Ottawa: Canadian Agency for Drugs and Technologies in Health; 2008.
102. **Tonelli M**, Manns B, Wiebe N, Shrive F, Pannu N, Doig C, Klarenbach S. *Overview of continuous renal replacement therapy in adult patients with acute renal failure*. [Technology overview number 31 (peer reviewed)]. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2007.
103. Manns B, **Tonelli M**, Shrive F, Wiebe N, Klarenbach S, Lee H, Culleton B. *Sevelamer in patients with end-stage renal disease: a systematic review and economic evaluation*. [Technology report no 71; peer reviewed]. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2006.

Reviews, Book Chapters and Commentaries:

104. Garg A, Hackam D, **Tonelli M**. *Systematic review and meta-analysis: when one study is just not enough*. Clin J Am Soc Nephrol. 2008 Jan; 3(1):253-60.
105. **Tonelli M**, Garg A. Primer on Systematic Review and Meta-analysis. In: Parfrey P, Barrett B, eds. *Clinical Epidemiology: Practice and Methods*. New Jersey: Humana Press; 2008.
106. Klarenbach S, **Tonelli M**, Hemmelgarn B, Jindal K. *CHAPTER 6: Diabetes and Kidney Disease in Alberta*. In Alberta Diabetes Atlas 2007: Institute of Health Economics. 2007:p.83-94.
107. Pannu N, **Tonelli M**. *Continuous venovenous hemodiafiltration and intermittent hemodialysis did not differ for improving survival in ARF with multiorgan dysfunction*. ACP J Club. 2007 Jan-Feb; 146(1):15.
108. **Tonelli M**. *The effect of statins on preservation of kidney function in patients with coronary artery disease*. Curr Opin Cardiol. 2006 Nov; 21(6):608-12.
109. Yeates K, **Tonelli M**. *Indigenous health: update on the impact of diabetes and chronic kidney disease*. Curr Opin Nephrol Hypertens. 2006 Nov; 15(6):588-92.
110. Pannu N, **Tonelli M**, Pfeffer M. *Kidney Disease and Cardiovascular Risk*. Annu Rev Med. 2007 Feb; 58:123-39. Epub 2006 Nov 2.
111. Shurraw S, **Tonelli M**. *Statins for treatment of dyslipidemia in chronic kidney disease*. Perit Dial Int. 2006 Sep-Oct; 26(5):523-39.
112. **Tonelli M**. *Do statins protect the kidney as well as the heart?* Nephrol Dial Transplant. 2006 Nov;21(11):3005-6. Epub 2006 Sep 12.
113. Thadhani R, **Tonelli M**. *Cohort studies: marching forward*. Clin J Am Soc Nephrol. 2006 Sep; 1(5):1117-23. Epub 2006 Aug 2.
114. Pannu N, **Tonelli M**. *Strategies to reduce the risk of contrast nephropathy: an evidence-based approach*. Curr Opin Nephrol Hypertens. 2006 May; 15(3):285-90.
115. Canadian Medical Association; contributing author. *Determining medical fitness to operate motor vehicles.CMA driver's guide*. 7th ed. Ottawa (ON): The Association; 2006.
116. **Tonelli M**, McFarlane P. *Amlodipine or Lisinopril Was Not Better Than Chlorthalidone in Reducing Renal Outcomes in Hypertension and Impaired Function*. ACP Journal Club. 2005 Sep/Oct; 143(2):45.
117. **Tonelli M**. *Monitoring and Maintenance of Arteriovenous Fistulae and Graft Function in Hemodialysis Patients*. Curr Opin Nephrol Hypertens. 2004 Nov; 13(6):655-60.
118. **M. Tonelli**, Kiberd B. *Control of Coronary Risk Factors in Chronic Kidney Disease*. Harrison's Online. <http://www.harrisonsonline.com>

Research Letters:

119. **Tonelli M**, James M, Jindal K, Hemmelgarn B. *In reply: ultrasound monitoring to detect access stenosis in hemodialysis patients.* Am J Kidney Dis 2008 (in press)
120. **Tonelli M.** *Reply to Olgaard and Lewin.* Nephrol Dial Transplant. 2008 June; 23(6):1792-3.
121. Khan N, Hemmelgarn B, **Tonelli M**, Thompson C, Levin A. *Response to Letter Regarding Article by Khan et al, "Prognostic Value of Troponin T and I Among Asymptomatic Patients With End-Stage Renal Disease: A Meta-Analysis"* Circulation. 2006 May 23; 113(20):e776.
122. Walsh M, Manns B, **Tonelli M**, Culleton B. *Re: Daily Dialysis, Nocturnal Dialysis, and Randomised Controlled Trials: Are we asking the Right Questions?* Kidney Int. 2005 Dec; 68(6): 2914.
123. **Tonelli M**, Manns B, Pannu N, Klarenbach S, Jindal K. *Re: Continuous Renal Replacement Therapy Improves Renal Recovery from Acute Renal Failure.* Can J Anaesth. 2005 Nov; 52(9):1001-2.
124. **Tonelli M**, Hemmelgarn B, Yeates K, Gill J. *The Ethics of Research Involving Canada's Aboriginal Populations.* CMAJ. 2005 Apr 12; 172(8):977-8.
125. **Tonelli M**, Owen W, Jindal K, Winkelmayer W, Manns B. *Regarding Impact of epoetin alfa on Clinical Endpoints in Patients with Chronic Renal Failure: A Meta-analysis.* Kidney Int. 2004 Oct; 66(4):1712.
126. **Tonelli M**, Manns B, Pannu N. *How Can We Be Sure That Renal Dysfunction After Coronary Angiography Is Just Explained by Contrast Nephropathy?* Kidney Int. 2004 Oct; 66(4):1717-8.
127. Pannu N, Manns B, **Tonelli M.** *Prevention of Acute Renal Failure with N-acetylcysteine – Enough is Enough?* Kidney Int. 2004 Sep; 66(3):1293-4.
128. **Tonelli M**, Pannu N, Manns B. *Influence of Dialysis Membranes on Outcomes in Acute Renal Failure.* Kidney Int. 2003 May; 63(5):1957-8.
129. **Tonelli M**, Jindal K. *Interpreting the "Error Message" on Transonic Testing* Semin Dial. 2002 May-Jun; 15(3)212.

Published Abstracts:

1. Khangura J, Culleton B, Zhang J, Manns B, Walsh M, Klarenbach S, **Tonelli M**, Hemmelgarn B. *"Association between blood pressure measurement methods and left ventricular hypertrophy in hemodialysis patients."* Canadian Society of Nephrology Annual Meeting, London, Canada. May 2008.
2. Schorr M, Manns B, Culleton B, Walsh M, Klarenbach S, **Tonelli M**, Sauve L, Wang D, Hemmelgarn B. *"The effect of nocturnal hemodialysis vs conventional hemodialysis on nutritional status."* Canadian Society of Nephrology Annual Meeting, London, Canada. May 2008.
3. James M, Laupland K, Manns B, **Tonelli M**, Culleton B, Hemmelgarn B. *"Association between chronic kidney disease and community-onset bloodstream infections in elderly subjects."* J Am Soc Nephrol. 2007;18:774A.
4. Al-Ghamdi G, Pannu N, Hemmelgarn B, Klarenbach S, Wiebe N, **Tonelli M.** *"Higher dialysate potassium is associated with increased risk of death in hemodialysis patients."* Canadian Society of Nephrology Annual Meeting, Halifax, Canada. May 2007.
5. Conley J, James M, MacRae J, Manns B, **Tonelli M**, Culleton B, Hemmelgarn B. *"Antimicrobial agents for the prophylaxis of catheter related bloodstream infections in hemodialysis patients: A systematic review and meta-analysis."* J Am Soc Nephrol. 2007;18:463A.
6. Poyah P, Deved V, James M, **Tonelli M**, Hemmelgarn B. *"A systematic review and meta-analysis of the effect of ascorbic acid in erythropoietin-resistant anemia among*

- hemodialysis patients.*” Canadian Society of Nephrology Annual Meeting, Halifax, Canada. May 2007.
7. Ahmed S, Zhang J, Culleton B, Manns B, **Tonelli M**, Hemmelgarn B. “*Hormone replacement therapy and progression of chronic kidney disease.*” J Am Soc Nephrol. 2007;18:816A.
 8. Yeates K, Wiebe N, Sima C, Schaubel D, Holland D, Hemmelgarn B, Gill J, **Tonelli M**. “*A comparison of outcomes in renal transplantation among Black and White Patients in Canada.*” J Am Soc Nephrol. 2007;18:669A.
 9. Michaud M, Hemmelgarn B, Zhang J, **Tonelli M**, Manns B, Culleton B. “*Higher Serum Phosphate Is Associated with Increased Mortality Risk in the Elderly.*” Journal of American Society of Nephrology. Nov 2006.
 10. James M, Walsh M, **Tonelli M**, Jayne D, Hemmelgarn B. “*Mycophenolate Mofetil for Induction Therapy of Proliferative Lupus Nephritis: A Systematic Review and Meta-Analysis.*” Journal of American Society of Nephrology. Nov 2006.
 11. Chou S, Hemmelgarn B, Manns B, Culleton B, Wiebe N, Klarenbach S, Gill JS, **Tonelli M**. “*Differences in Survival and Use of Peritoneal Dialysis among East Asian, Indo Asian and White End-Stage Renal Disease Patients in Canada.*” Journal of American Society of Nephrology. Nov 2006.
 12. Wang W, **Tonelli M**, Hemmelgarn B, Taub K, Johnson J, Manns B. “*Increasing Small Solute Clearance in Underdialysed Large Hemodialysis Patients Does Not Improve Quality of Life: A Randomized Cross-Over Study.*” Journal of American Society of Nephrology. Nov 2006.
 13. Lok C, Allon M, Chan C, Donnelly S, Dorval M, Hemmelgarn B, Moist L, Oliver M, **Tonelli M**, Stanley K. “*Design of the Fish Oil Inhibition of Stenosis in Hemodialysis (FISH) Graft Study.*” Journal of American Society of Nephrology. Nov 2006.
 14. Chou S, Chiang C, **Tonelli M**, Gourishankar S, Hemmelgarn B. “*An International Comparison of Hemodialysis Care in Asian Patients.*” Journal of American Society of Nephrology. Nov 2006.
 15. Gao S, Manns B, Culleton B, Quan H, **Tonelli M**, Hemmelgarn B. “*Access To Care for Aboriginal Compared to Non-Aboriginal People with Chronic Kidney Disease.*” Journal of American Society of Nephrology. Nov 2006.
 16. Gao S, Manns B, Culleton B, Quan H, **Tonelli M**, Hemmelgarn B. “*Prevalence of Chronic Kidney Disease among Aboriginal and Non-Aboriginal People in Alberta.*” Journal of American Society of Nephrology. Nov 2006.
 17. Wolf M, Shah A, Gutierrez O, Ankers E, Monroy M, Steele D, **Tonelli M**, Thadhani R. “*Vitamin D Levels and Mortality among U.S. Hemodialysis Patients.*” Journal of American Society of Nephrology. Nov 2006.
 18. Shurraw S, Majumdar S, Gao Z, **Tonelli M**; Alberta Kidney Disease Network. “*The relationship between serum glucose and mortality in chronic hemodialysis patients*”. Canadian Society of Nephrology Annual Meeting; May 2006.
 19. Wang W, Murphy B, **Tonelli M**, MacRae J, Manns B. “*Comorbidities do not influence primary fistula success in a prospective cohort in Southern Alberta.*” Canadian Society of Nephrology Annual Meeting; May 2006.
 20. Al-Ghonaim M, Manns B, Hirsch D, Gao Z, **Tonelli M**. “*Relation between hemodialysis access blood flow and mortality.*” Canadian Society of Nephrology Annual Meeting; May 2006.
 21. Chou S, **Tonelli M**, Chiang C, Bradley J, Gourishankar S, Hemmelgarn B. “*An international comparison of hemodialysis care in Asian patients.*” Canadian Society of Nephrology Annual Meeting; May 2006.
 22. Chou S, Hemmelgarn B, Wiebe N, Culleton B, Manns B, Klarenbach S, Gill JS, Khan N, **Tonelli M**. “*Survival advantage in Asian and South Asian dialysis patients in Canada.*” Canadian Society of Nephrology Annual Meeting; May 2006.

23. Klarenbach S, **Tonelli M**, Manns B, Pannu N. "Economic Evaluation of Is-Osmolar Contrast Media to Prevent Contrast Nephropathy." *Journal of American Society of Nephrology*. 2005 Oct (16).
24. Walsh M, Manns B, **Tonelli M**, Quinn R, Culleton B. "Description of a randomized controlled trial on the effects of nocturnal hemodialysis on left ventricular hypertrophy compared to conventional hemodialysis." *Journal of the American Society of Nephrology*. 2005 Oct (16).
25. Chou S, Hemmelgarn B, Gourishankar S, Bradley J, Jhangri G, **Tonelli M**. "Barriers to Kidney Transplantation among Aboriginal Hemodialysis Patients in Alberta." *Journal of American Society of Nephrology*. 2005 Oct (16).
26. Chou S, **Tonelli M**, Bradley J, Gourishankar S, Hemmelgarn B. "Quality of Care among Aboriginal People Undergoing Hemodialysis in Alberta." *Journal of American Society of Nephrology*. 2005 Oct (16).
27. Sandhu S, Wiebe N, Fried L, **Tonelli M**. "Statins for Slowing Progression of Kidney Disease: A Meta-analysis." *Journal of American Society of Nephrology*. 2005 Oct (16).
28. **Tonelli M**, Keech A, Shepherd J, Sacks F, Tonkin A, Packard C, Pfeffer M, Simes J, Isles C, Furberg C, West M, Craven T, Curhan G; Edmonton and the Pravastatin Pooling Project. "Effect of Pravastatin in People with Chronic Kidney Disease and Diabetes Mellitus." Abstract No. 0140. European Council for Cardiovascular Research, 10th Annual Meeting; Nice, France; October 2005.
29. Klarenbach S, **Tonelli M**, Manns B, Pannu N; for the Alberta Kidney Disease Network. "Economic Evaluation of Iodixanol to Prevent Radiocontrast Nephropathy." Canadian Society of Nephrology Scientific Meeting, May 2005.
30. **Tonelli M**, Hemmelgarn B, Manns B, Pylpchuk G, Bohm C, Yeates K, Gourishankar S, Gill JS; Canadian Young Investigators' Group. "Health Outcomes among Aboriginal Canadians Receiving Dialysis Treatment." International Society of Nephrology Scientific Meeting, "Prevention of Kidney Disease in Minority Groups and Emerging Nations – Focus on the Americas." Nov 2003.
31. **Tonelli M**, Jhangri G, Hirsch D, Jindal K. "Access Blood Flow Monitoring: Access Failure, Vascular Access Complications." *J Am Soc Nephrol*. Nov 2003.
32. **Tonelli M**, Collins D, Robbins S, Bloomfield-Rubins H, Curhan G. "Effect of Gemfibrozil on Loss of Renal Function in Subjects with Moderate Chronic Renal Insufficiency (CRI) and Low HDL-cholesterol (HDL-C)." *J Am Soc Nephrol*. 2003 Nov; 14(11):A1028.
33. Gill J, **Tonelli M**, Nathan L, Mix C, Pereira B. "The Nature of the Benefit of Preemptive Kidney Transplantation." *J Am Soc Nephrol*. 2003 Nov; 14(11):A587.
34. Gill J, **Tonelli M**, Johnson N, Mix C, Pereira B. "Access to Preemptive Cadaveric Kidney Transplantation." *J Am Soc Nephrol*. 2003 Nov; 14(11):A599.
35. **Tonelli M**, Jhangri G, Hirsch D, Jindal K. "Appropriate Threshold Value for Diagnosing Stenosis Using Access Blood Flow (Qa) in Arteriovenous Fistulae (AVF)." *J Am Soc Nephrol*. 2003 Nov; 14(11):A242.
36. Klarenbach S, Manns B, **Tonelli M**. "Modeling the Progression of Chronic Kidney Disease Using First Order Monte Carlo Methods within Markov Process." *J Am Soc Nephrol*. 2003 Nov; 14(11): A106.
37. Pannu N, Manns B, Lee H, **Tonelli M**. "Systematic Review of the Impact of N-acetylcysteine on Contrast Nephropathy." *J Am Soc Nephrol*. 2003 Nov; 14(11):A997.
38. **Tonelli M**, Manns B. "Opportunity Cost, Uncertainty, and Sevelamer: The Cost-Effectiveness of New Therapies for Managing Hyperphosphatemia in Patients with End-stage Kidney Disease." Canadian Society of Nephrology Scientific Meeting, May 2003.

39. **Tonelli M.** “*Extended Reuse of Polysulfone Hemodialysis Membranes.*” Canadian Society of Nephrology Scientific Meeting, May 2003.
40. **Tonelli M,** Collins D, Robins S, Rubins H, Curhan G. “*Gemfibrozil Prevents New Cardiovascular Events in Patients with Chronic Renal Insufficiency (CRI) and Coronary Disease.*” J Am Soc Nephrol. 2002 Sep; 13:A840.
41. **Tonelli M,** Moye L, Sacks F, Cole T, Curhan G. “*Effect of Pravastatin on Loss of Renal Function in Patients with CKD.*” J Am Soc Nephrol. 2002 Sep; 13:A0966.
42. Hewlett T, **Tonelli M,** Hirsch D, Jindal K. “*Unacceptable Inaccuracy of Anthropometric V in Acute Intermittent Hemodialysis.*” J Am Soc Nephrol. 2001 Oct; 12:A2322.
43. **Tonelli M,** Hirsch D, Clark T, Jindal K. “*Outcome of Stenoses in AV Fistulae (AVF) Detected by Ultrasound Dilution (UD) Screening and Treated with Angioplasty (PTA).*” J Am Soc Nephrol. 2001 Oct; 12:A1567.
44. **Tonelli M,** Hirsch D, Jindal K. “*Diagnostic Performance of Ultrasound Dilution Techniques (UDT) in Arteriovenous Fistulae (AVF) with Previous Stenosis.*” J Am Soc Nephrol. 2001 Oct; 12:A1566.
45. Thadhani R, Wolf M, West M, **Tonelli M,** Obrador G. “*Patients with Fabry Disease on Dialysis in the United States.*” J Am Soc Nephrol. 2001 Oct; 12:A0450.
46. Thadhani R, Wolf M, **Tonelli M,** West M, Obrador G. “*Fabry Disease Patients on Dialysis in the US and Europe: A Comparison Study.*” J Am Soc Nephrol. 2001 Oct; 12:A0449.
47. **Tonelli M,** Moye L, Sacks F, Curhan G. “*Pravastatin Is Effective for Secondary Prevention of Cardiovascular Events in Patients with Chronic Renal Insufficiency (CRI).*” J Am Soc Nephrol. 2001 Oct; 12:A1296.
48. **Tonelli M,** Jindal K, Hirsch D, Taylor S, Kane C, Henbrey S. “*Specificity and Sensitivity of Ultrasound Dilution Techniques for Detection of Stenosis in Native Arteriovenous Fistulae.*” J Am Soc Nephrol. 2000; 11:1059A.
49. **Tonelli M,** Bohm C, Pandeya S, Gill J, Levin A, Kiberd B. “*Use of Cardioprotective Medications in CRI.*” J Am Soc Nephrol. 2000;11: 78A.
50. **Tonelli M,** Gill J, Pandeya J, Bohm C, Levin A, Kiberd B. “*Barriers to Use of ACE Inhibitors and Control of Hypertension in CRF Patients.*” J Am Soc Nephrol. 2000; 11:169A.
51. **Tonelli M,** Gill J, Blake P, Muirhead N. “*Predictors of Erythropoietin Requirements in Chronic Hemodialysis Patients.*” J Am Soc Nephrol. 1998; 9:272A.
52. **Tonelli M,** Djurdjev O, Carlisle E, Ethier J, Mendelssohn D, Burgess E, Jindal K, Tobe S, Barrett B, Singer J, Levin A. (Canadian Nephrology Investigators Group). “*Factors Affecting Rate of Progressive Renal Decline: Observations in a Non-Clinical Trial Setting.*” J Am Soc Nephrol. 1998; 9:80A.
53. **Tonelli M,** Muirhead N. “*Access Type as a Predictor of Hemodialysis Adequacy.*” Clin Invest Med. 1997; 20(4 Supp 2):S61.

Oral and Poster Presentations:

54. Walsh M, Culleton B, Klarenbach S, Mortis G, Quinn R, Scott-Douglas N, **Tonelli M,** Manns B. **Oral presentation,** “*Nocturnal hemodialysis improves serum phosphate and reduces exposure to phosphate binders: results of a randomized clinical trial.*” Canadian Society of Nephrology Meeting; Halifax, Canada; May 2007.
55. James M, Laupland K, Manns B, **Tonelli M,** Culleton B, Hemmelgarn B. **Oral presentation,** “*Association between chronic kidney disease and community-onset bloodstream infections in elderly subjects.*” Canadian Society of Nephrology Meeting; Halifax, Canada; May 2007.
56. Culleton B, Walsh M, Klarenbach S, **Tonelli M,** Quinn R, Scott-Douglas N, Mortis G, Kumar A, Donnelly S, Manns B. **Oral presentation,** “*Nocturnal hemodialysis lowers*

- blood pressure and reduces left ventricular mass: results of a randomized clinical trial.*” Canadian Society of Nephrology Meeting; Halifax, Canada; May 2007.
57. Al-Ghamdi G, Pannu N, Hemmelgarn B, Klarenbach S, Wiebe N, **Tonelli M. Oral presentation**, “*Higher dialysate potassium is associated with increased risk of death in hemodialysis patients.*” Canadian Society of Nephrology Meeting; Halifax, Canada; May 2007.
 58. Manns B, Klarenbach S, Walsh M, Quinn R, **Tonelli M**, Scott-Douglas N, Mortis G, Lee H, Culleton B. **Poster presentation**, “*The impact of nocturnal hemodialysis on quality of life: results of a randomized clinical trial.*” Canadian Society of Nephrology Meeting; Halifax, Canada; May 2007.
 59. Mathew A, Devereaux P, O’Hare A, **Tonelli M**, Thiessen-Philbrook H, Nevis I, Iansavichus A, Garg A. **Poster presentation**, “*Chronic kidney disease and postoperative mortality: a systematic review and meta-analysis.*” Canadian Society of Nephrology Meeting; Halifax, Canada; May 2007.
 60. Conley J, James M, MacRae J, Manns B, **Tonelli M**, Culleton B, Hemmelgarn B. **Poster presentation**, “*Antimicrobial agents for the prophylaxis of catheter related bloodstream infections in hemodialysis patients: a systematic review and meta-analysis.*” Canadian Society of Nephrology Meeting; Halifax, Canada; May 2007.
 61. James M, Walsh M, Manns B, **Tonelli M**, Jayne D, Hemmelgarn B. **Poster presentation**, “*Induction therapy with mycophenolate mofetil for proliferative lupus nephritis: a systematic review and meta-analysis.*” Canadian Society of Nephrology Meeting; Halifax, Canada; May 2007.
 62. Poyah P, Deved V, James M, Tonelli M, Hemmelgarn B. **Poster presentation**, “*A systematic review and meta-analysis of the effect of ascorbic acid in erythropoietin-resistant anemia among hemodialysis patients.*” Canadian Society of Nephrology Meeting; Halifax, Canada; May 2007.
 63. Rucker D, **Tonelli M**, Coles M, Yoo S, Young K, McMahon A. **Poster presentation**, “*Vitamin D insufficiency and treatment with oral vitamin D3 in patients with non-dialysis dependent chronic kidney disease living in Northern Canada.*” Canadian Society of Nephrology Meeting; Halifax, Canada; May 2007.
 64. Ahmed S, Zhang J, Culleton B, Manns B, **Tonelli M**, Hemmelgarn B. **Poster presentation**, “*Hormone replacement therapy and progression of chronic kidney disease.*” Canadian Society of Nephrology Meeting; Halifax, Canada; May 2007.
 65. Wang W, **Tonelli M**, Hemmelgarn B, Gao S, Taub K, Johnson J, Manns B. **Poster presentation**, “*Increasing small solute clearance in underdialysed large hemodialysis patients does not improve quality of life: a randomized cross-over study.*” Canadian Society of Nephrology Meeting; Halifax, Canada; May 2007.
 66. Klarenbach S, **Tonelli M**, Dong J, Gourishankar S. **Poster presentation**, “*Health care resource use associated with post-transplant diabetes mellitus.*” Canadian Society of Nephrology Meeting; Halifax, Canada; May 2007.
 67. Michaud M, Hemmelgarn B, Zhang J, **Tonelli M**, Culleton B. **Poster presentation**, “*Impact of serum phosphate on mortality in a community dwelling elderly population.*” Canadian Society of Nephrology Meeting; Halifax, Canada; May 2007.
 68. **Tonelli M**, Keech A, Shepherd J, Sacks F, Tonkin A, Packard C, Pfeffer M, Simes J, Isles C, Furberg C, West M, Craven T, Curhan G; (Edmonton and the Pravastatin Pooling Project). **Poster presentation**, Group PD8 – Clinical Cardiovascular Studies. “*Effect of Pravastatin in People with Chronic Kidney Disease and Diabetes Mellitus.*” European Council for Cardiovascular Research, 10th Annual Meeting; Nice, France; October 2005.
 69. **Tonelli, M. Oral Presentation.** “*First Nations.*” KRESCENT Trainee Education Day; August 2005.

70. Gill J, **Tonelli M**, Landsberg D, Johnson N, Kiberd B, Pereira B. **Oral presentation**, “*Transplantation: is it Worth the Wait?*” Canadian Society of Nephrology Meeting; Toronto, Canada; May 2004.
71. Klarenbach S, **Tonelli M**, Pannu N, Manns B. **Poster presentation**, “*Cost-effectiveness of Prophylactic Hemofiltration to Prevent Radiocontrast Nephropathy.*” Canadian Society of Nephrology Meeting; Toronto, Canada; May 2004.
72. Manns B, Lee H, Murphy B, Yilmaz S, Radkevich V, Klarenbach S, **Tonelli M**. **Poster presentation**, “*Establishment and Maintenance of Vascular Access in Incident Hemodialysis Patients: A Prospective Cost Analysis.*” Canadian Society of Nephrology Meeting; Toronto, Canada; May 2004.
73. Bradley J, Hemmelgarn B, Gourishankar S, **Tonelli M**. **Poster presentation**, “*Quality of Hemodialysis Care in Aboriginal Patients.*” Canadian Society of Nephrology Meeting; Toronto, Canada; May 2004.
74. **Tonelli M**, Pereira B, Gill J. **Oral presentation**, “*Surrogate Measures of Long-term Allograft Survival.*” American Transplant Congress; Boston, USA; May 2004.
75. Gill J, **Tonelli M**, Johnson N, Mix C, Pereira B. **Poster presentation**, “*The Nature of the Benefit of Preemptive Kidney Transplantation.*” American Society of Nephrology Scientific Meeting; San Diego, USA; November 2003.
76. Jagbir S, Gill J, **Tonelli M**, Johnson N, Mix C, Pereira. **Poster presentation**, “*Access to Preemptive Cadaveric Kidney Transplantation.*” American Society of Nephrology Scientific Meeting; San Diego, USA; November 2003.
77. Pannu N, Manns B, Lee H, **Tonelli M**. **Poster presentation**, “*Systematic Review of the Impact of N-Acetylcysteine on Contrast Nephropathy.*” American Society of Nephrology Scientific Meeting; San Diego, USA; November 2003.
78. **Tonelli M**, Collins D, Robins S, Bloomfield-Rubins H, Curhan G. **Poster presentation**, “*Effect of Gemfibrozil on Loss of Renal Function in Subjects with Moderate Chronic Renal Insufficiency (CRI) and Low HDL-Cholesterol (HDL-C).*” American Society of Nephrology Scientific Meeting; San Diego, USA; November 2003.
79. **Tonelli M**, Jhangri G, Hirsch D, Jindal K. **Oral presentation**, “*Appropriate Threshold Value for Diagnosing Stenosis Using Access Blood Flow (Qa) in Arteriovenous Fistulae (AVF).*” American Society of Nephrology Scientific Meeting; San Diego, USA; November 2003.
80. Klarenbach S, Manns M, **Tonelli M**. **Poster presentation**, “*Modelling the Progression of Chronic Kidney Disease Using First Order Monte Carlo Methods with a Markov Process.*” American Society of Nephrology Scientific Meeting; San Diego, USA; November 2003.
81. **Tonelli M**, Collins D, Robins S, Rubins H, Curhan G. **Poster presentation**, “*Gemfibrozil Prevents New Cardiovascular Event in Patient with Chronic Renal Insufficiency (CRI) and Coronary Disease.*” American Society of Nephrology Scientific Meeting; Philadelphia, USA; November 2002.
82. **Tonelli M**, Moye L, Sacks F, Cole T, Curhan G. **Poster presentation**, “*Effect of Pravastatin on Loss of Renal Function in Patients with CKD.*” American Society of Nephrology Scientific Meeting; Philadelphia, USA; November 2002.
83. **Tonelli M**, Hirsch D, Clark T, Jindal K. **Oral presentation**, “*Detection and Outcome of Recurrent Stenoses in Native Vessel Arteriovenous Fistulae.*” Canadian Society of Nephrology Scientific Meeting, March 2002.
84. **Tonelli M**, Moye L, Sacks F, Curhan G. **Oral presentation**, “*Pravastatin is Effective for Secondary Prevention of Cardiovascular Event in Patients with Chronic Renal Insufficiency (CRI).*” ASN/ISN World Congress of Nephrology; San Francisco, USA; October 2001.
85. **Tonelli M**, Moye L, Sacks F, Curhan G. **Oral presentation**, “*Pravastatin is Effective for Secondary Prevention of Cardiovascular Events in Patients with Chronic Renal*

Insufficiency (CRI).” American Society of Nephrology Scientific Meeting, October 2001.

Professional and Scholarly Activities

Committees:

University of Alberta, Department of Medicine

- MD Special Training in Research Committee (STIR), Member; 2005-.
- Research Facilitator Working Group Committee, Member; 2003-2005.
- Department of Medicine Research Committee; 2005-.
- MD/MBA Committee; 2005-.
- Department of Medicine Post Graduate Research Committee; 2006-.

University of Alberta; Department of Medicine, Division of Nephrology and Immunology

- Vascular Access Committee, Chair; 2005. (Member since 2002).
- Recruitment Committee, Member; 2004-.
- Northern Alberta Renal Program Quality Assurance Committee, Co-Chair; 2002-2005.
- Northern Alberta Renal Program Quality Assurance Committee, Member; 2006.
- Hemodialysis Practice Guidelines Committee, Member; 2004.
- Recruitment Committee for Divisional Director, Member; 2003-2006.
- Electronic Records/Databases Committee, Member; 2003-2006.
- Health Outcomes Research Group Committee, Member; 2003.
- Northern Alberta Renal Program Peritoneal Dialysis Committee, Chair, 2006-2007.
- Clinical Divisional Planning Committee, Member; 2004.
- Academic Divisional Planning Committee, Member; 2004.

University of Alberta; Department of Public Health Sciences

- Postgraduate Students Selection Committee, Member; 2005-.

University of Alberta Hospital (Capital Health)

- Search Committee, Research Chair in Aboriginal Health, 2008.
- Recruitment Selection Committee for Director of Patient Safety Research and Medical Quality; 2007.
- Search Committee, Scientific Director, Center for Health Outcomes Research (CHOR); 2005.
- Nephrology Information System (NIS) Project; Steering Committee, Member; 2004-2005.
- iCARE Scientific Advisory Committee; 2006-2008.
- Alberta Health Improvement Project Committee; 2006-.

National

- Canadian Society of Nephrology, President-Elect; 2008-.
- Canadian Society of Nephrology Clinical Practice Guidelines Committee, Chair; 2007-.
- Canadian Organ Replacement Registry Research Committee (CORR); 2005-.
- Canadian Society of Nephrology Annual Meeting, Chronic Kidney Disease in Aboriginal People; Session Chair, 2005.
- Canadian Society of Nephrology Annual Meeting, Clinical Science Session; Session Chair; 2004.
- Kidney Foundation of Canada, Fellowship and Scholarship Committee; Member; 2002-2006.

- Canadian Society of Nephrology/Kidney Foundation of Canada Training Grant Curriculum Committee (KRESCENT) Committee, Member; 2003-.
- Young Investigators Group (OrthoBiotech), Co-Chair; 2003-2005.
- Canadian Society of Nephrology Scientific Committee, Member; 2002 -.
- Canadian Society of Nephrology Ad Hoc International Health Committee, Chair; 2006-.

International

- World Health Organization. Global burden of diseases study. Member, Expert panel, genitourinary diseases. 2007-.
- Scientific Advisory Board of the International Academy and of the World Congress on Heart Disease; 2006, 2007.
- International Society of Nephrology. Committee for Kidney health in disadvantaged populations, Member; 2006-.
- National Kidney Foundation's Cardio Kidney Diabetes (CKD) Global Consensus Conference. Panel Member; October 17-19, 2007 (Chicago, Illinois).

Service and Administration

- Co-founder of clinic aimed at preventing chronic kidney disease and its complications among the poor of Guadalajara, Mexico. 2004-.
- Canadian Society of Nephrology Council, Counsellor; 2005-.
- Kidney Foundation of Canada, Alberta Chapter, Board of Directors; 2007-.